Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: an international, multicenter, randomized, double-blind, placebo-controlled trial
Background: Sodium oxybate (SMO) has been shown to be effective in the maintenance of abstinence (MoA) in alcohol-dependent patients in a series of small randomized controlled trials (RCTs). These results needed to be confirmed by a large trial investigating the treatment effect and its sustainabili...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 7, 2022
|
| In: |
Journal of psychopharmacology
Year: 2022, Volume: 36, Issue: 10, Pages: 1136-1145 |
| ISSN: | 1461-7285 |
| DOI: | 10.1177/02698811221104063 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1177/02698811221104063 Verlag, kostenfrei, Volltext: https://journals.sagepub.com/doi/full/10.1177/02698811221104063 |
| Author Notes: | Julien Guiraud, Giovanni Addolorato, Mariangela Antonelli, Henri-Jean Aubin, Andrea de Bejczy, Amine Benyamina, Roberto Cacciaglia, Fabio Caputo, Maurice Dematteis, Anna Ferrulli, Anna E Goudriaan, Antoni Gual, Otto-Michael Lesch, Icro Maremmani, Antonio Mirijello, David J Nutt, François Paille, Pascal Perney, Roch Poulnais, Quentin Raffaillac, Jürgen Rehm, Benjamin Rolland, Claudia Rotondo, Bruno Scherrer, Nicolas Simon, Katrin Skala, Bo Söderpalm, Lorenzo Somaini, Wolfgang H Sommer, Rainer Spanagel, Gabriele A Vassallo, Henriette Walter and Wim van den Brink |
| Summary: | Background: Sodium oxybate (SMO) has been shown to be effective in the maintenance of abstinence (MoA) in alcohol-dependent patients in a series of small randomized controlled trials (RCTs). These results needed to be confirmed by a large trial investigating the treatment effect and its sustainability after medication discontinuation. - Aims: To confirm the SMO effect on (sustained) MoA in detoxified alcohol-dependent patients. - Methods: Large double-blind, randomized, placebo-controlled trial in detoxified adult alcohol-dependent outpatients (80% men) from 11 sites in four European countries. Patients were randomized to 6 months SMO (3.3-3.9 g/day) or placebo followed by a 6-month medication-free period. Primary outcome was the cumulative abstinence duration (CAD) during the 6-month treatment period defined as the number of days with no alcohol use. Secondary outcomes included CAD during the 12-month study period. - Results: Of the 314 alcohol-dependent patients randomized, 154 received SMO and 160 received placebo. Based on the pre-specified fixed-effect two-way analysis of variance including the treatment-by-site interaction, SMO showed efficacy in CAD during the 6-month treatment period: mean difference +43.1 days, 95% confidence interval (17.6-68.5; p = 0.001). Since significant heterogeneity of effect across sites and unequal sample sizes among sites (n = 3-66) were identified, a site-level random meta-analysis was performed with results supporting the pre-specified analysis: mean difference +32.4 days, p = 0.014. The SMO effect was sustained during the medication-free follow-up period. SMO was well-tolerated. - Conclusions: Results of this large RCT in alcohol-dependent patients demonstrated a significant and clinically relevant sustained effect of SMO on CAD. - Trial registration: ClinicalTrials.gov Identifier: NCT04648423 |
|---|---|
| Item Description: | Gesehen am 08.08.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1461-7285 |
| DOI: | 10.1177/02698811221104063 |